Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Dominique R Bollino, Yuchen Liu, Osman Mohamed Bah, Katherine Caprinolo, Jinoos Zarrabi, Sunita Philip, Ezzat Mostafa, Rena G. Lapidus, Zeba Singh, Michael Kallen, Yi Ning, Rima Koka, Maria R. Baer, Sandrine Niyongere, Vu H. Duong, Erin T Strovel, Molly Graveno, Ashkan Emadi

Blood (2022) 140 (Supplement 1): 9044–9045.

https://doi.org/10.1182/blood-2022-159621

Published: 2022

Journal Articles

Dehydrated Hereditary Stomatocytosis: A Rare Inherited Hemolytic Anemia

Farah Shaukat, Zeba Singh, Hira Latif

Blood (2021) 138 (Supplement 1): 4148.

https://doi.org/10.1182/blood-2021-150968

Published: 2021

Journal Articles

Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival

Sandrine Niyongere, MD, Yamini Kathari, MD, Zeba Singh, MD, Emily J. Vannorsdall, MD, Ashkan Emadi, MD, PhD, Vu Doung, MD, M.S., Maria R. Baer, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142747

Published: 2020

Journal Articles

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Ashkan Emadi, MD PhD, Vu H. Duong, MD, Jeremy Pantin, MD, Mohammad Imran, MD, Rima Koka, MD PhD, Zeba Singh, MBBS, Edward A. Sausville, MD PhD, Jennie Y. Law, MD, Seung Tae Lee, MD PhD, Huidong Shi, PhD, Ravindra Kolhe, MD PhD, Maria R. Baer, MD, Michael R. Loken, PhD, Eugene P. Kennedy, MD, Charles Link, MD, David H. Munn, MD

Blood (2018) 132 (Supplement 1): 332.

https://doi.org/10.1182/blood-2018-99-117433

Published: 2018

Journal Articles

Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study

Vu H. Duong, MD, Kebede H. Begna, MD, Kendra L. Sweet, MD, Eunice S. Wang, MD, Ryan James Caddell, PharmD, Danielle Shafer, DO, Zeba Singh, MBBS, Maria R. Baer, MD, Aref Al-Kali, MD

Blood (2018) 132 (Supplement 1): 2658.

https://doi.org/10.1182/blood-2018-99-115448

Published: 2018

Journal Articles

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Noa G. Holtzman, MD, Olga Goloubeva, PhD MSc, Zeba Singh, MBBS, Sameer Sawhney, MD, Ying Zou, MD PhD, Jean Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 3035.

https://doi.org/10.1182/blood.V130.Suppl_1.3035.3035

Published: 2017

Journal Articles

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Ashraf Badros, Elizabeth Hyjek, Ning Ma, Alexander Lesokhin, Ahmet Dogan, Aaron P. Rapoport, Mehmet Kocoglu, Emily Lederer, Sunita Philip, Todd Milliron, Cameron Dell, Olga Goloubeva, Zeba Singh

Blood (2017) 130 (10): 1189–1197.

https://doi.org/10.1182/blood-2017-03-775122

Published: 2017

Includes: Supplemental data

Journal Articles

Marizomib for CNS-Multiple Myeloma

Ashraf Z Badros, MD, Zeba Singh, MD, Binod Dhakal, MDMS, Young Kwok, MD, Ann MacLaren, PhD, Paul G. Richardson, MD, Mohit Trikha, PhD, Hari Parameswaran, MD

Blood (2016) 128 (22): 2118.

https://doi.org/10.1182/blood.V128.22.2118.2118

Published: 2016

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z Badros, MD, Elizabeth Hyjek, MD PhD, Ning Ma, Alexander M. Lesokhin, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2016) 128 (22): 490.

https://doi.org/10.1182/blood.V128.22.490.490

Published: 2016

Journal Articles

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z. Badros, MD, Mehmet H. Kocoglu, MD, Ning Ma, NP, Aaron P. Rapoport, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Cameron Dell, Nancy M. Hardy, MD, Jean Yared, MD, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2015) 126 (23): 506.

https://doi.org/10.1182/blood.V126.23.506.506

Published: 2015

Journal Articles

Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience

Ying S Zou, MD PhD, Yi Huang, PhD, Zhou Feng, Sin Chan, Shweta Shukla, Ina Lee, MDPhD, Zeba Singh, MD, Mehmet H. Kocoglu, MD, Aaron P. Rapoport, MD, Ning Ma, Nancy M. Hardy, MD, Jean Yared, MD, Maria R Baer, MD, Ashraf Z Badros, MD

Blood (2015) 126 (23): 1767.

https://doi.org/10.1182/blood.V126.23.1767.1767

Published: 2015

Journal Articles

Report of Rare Urachal Carcinoma Presenting with Thrombocytopenia and Microangiopathic Hemolytic Anemia

Ari H. Elman, MD, Zeba Singh, MD, Heather D. Mannuel, MD MBA, Mya S. Thein, MD

Blood (2014) 124 (21): 5026.

https://doi.org/10.1182/blood.V124.21.5026.5026

Published: 2014

Journal Articles

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Blood (2013) 121 (23): 4753–4757.

https://doi.org/10.1182/blood-2012-11-466961

Published: 2013

Includes: Supplemental data

NARROW

Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Dehydrated Hereditary Stomatocytosis: A Rare Inherited Hemolytic Anemia

Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Marizomib for CNS-Multiple Myeloma

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience

Report of Rare Urachal Carcinoma Presenting with Thrombocytopenia and Microangiopathic Hemolytic Anemia

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only